Pipeline Therapeutics to Present at BMO’s Fall Private Company Showcase 2020

SAN DIEGO--()--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Fall Private Company Showcase 2020, co-hosted by BMO, a fully virtual management access conference, on Thursday, October 15, at 1:40 p.m. ET / 10:40 a.m. PT.

About Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis. For more information, please visit www.pipelinetherapeutics.com.

Contacts

Company Contact:
Carmine Stengone
President and CEO
info@pipelinetherapeutics.com

Investor Contact:
Laurence Watts
619-916-7620
laurence@gilmartinir.com

Release Summary

Pipeline Therapeutics to Present at BMO’s Fall Private Company Showcase 2020

Contacts

Company Contact:
Carmine Stengone
President and CEO
info@pipelinetherapeutics.com

Investor Contact:
Laurence Watts
619-916-7620
laurence@gilmartinir.com